Stock Market Live July 1, 2026: S&P 500 (SPY) Lower as Investors Wait on the Fed and Fresh Economic Data
Ashland (ASH) Q2 2025 Earnings
Reported Apr 30, 2025 at 5:14 PM ET · SEC Source
Q2 25 EPS
$0.99
MISS 10.28%
Est. $1.10
Q2 25 Revenue
$479.0M
MISS 4.70%
Est. $502.6M
vs S&P Since Q2 25
-7.8%
TRAILING MARKET
ASH +25.9% vs S&P +33.7%
Market Reaction
Did ASH Beat Earnings? Q2 2025 Results
Ashland delivered a disappointing fiscal second quarter, missing on both the top and bottom lines as portfolio restructuring headwinds and softening organic demand weighed on results. The specialty chemicals company posted adjusted diluted EPS of $0.… Read more Ashland delivered a disappointing fiscal second quarter, missing on both the top and bottom lines as portfolio restructuring headwinds and softening organic demand weighed on results. The specialty chemicals company posted adjusted diluted EPS of $0.99, falling 10.28% short of the $1.10 consensus estimate, while revenue of $479.00 million trailed expectations by 4.70% and dropped 16.7% year-over-year. The single largest driver of the revenue decline was Ashland's completed Portfolio Optimization program, which stripped out roughly $67.00 million in sales through exits from businesses including carboxymethylcellulose, nutraceuticals, and the Avoca divestiture; even excluding those initiatives, organic sales slipped approximately 5%. Adjusted EBITDA fell 14% to $108.00 million, and free cash flow turned negative at $12.00 million. Looking ahead, management trimmed its full-year fiscal 2025 outlook, now guiding sales to a range of $1.83 billion to $1.90 billion and Adjusted EBITDA of $400.00 million to $420.00 million, citing weakening consumer sentiment, persistent intermediates pricing pressure, and sluggish European demand as key headwinds into the back half.
Key Takeaways
- • Portfolio Optimization initiatives reduced overall sales by approximately $67 million or 12% versus prior year
- • Life Sciences demonstrated strong pharma demand recovery, with organic volumes stable year-over-year
- • Cost savings program momentum and well-managed production recovery following strategic maintenance turnaround pull-forward
- • Personal Care core skin and hair care showed low-single-digit growth
- • Specialty Additives experienced anticipated volume declines in China and competitive intensity in export markets
- • Intermediates margins below expectations due to persistent pricing pressure in BDO and NMP
- • Foreign currency movements had unfavorable impact of $6 million on total sales
- • Life Sciences and Personal Care achieved Adjusted EBITDA margins above 30%
ASH YoY Financials
Q2 2025 vs Q2 2024, source: SEC Filings
ASH Revenue by Segment
With YoY comparisons, source: SEC Filings
“Our second-quarter performance reflected a mixed demand environment and lower-than-expected sales volumes, while pricing generally aligned with planning assumptions excluding intermediates. This combined impact was partially offset by the momentum of our cost savings program and a well-managed production recovery that followed our strategic pull-forward of maintenance turnarounds into the first quarter.”
— Guillermo Novo, Q2 2025 Earnings Press Release
ASH Earnings Trends
ASH vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
ASH EPS Trend
Earnings per share: estimate vs actual
ASH Revenue Trend
Quarterly revenue: estimate vs actual
ASH Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $0.25 | $0.26 | +5.22% | $386.0M | -4.03% |
| Q4 25 MISS FY | $1.26 | $1.08 | -14.62% | $478.0M | -0.76% |
| FY Full Year | $3.55 | $3.38 | -4.89% | $1.82B | -0.13% |
| Q3 25 MISS | $1.21 | $1.04 | -13.70% | $463.0M | -2.85% |
| Q2 25 MISS | $1.10 | $0.99 | -10.28% | $479.0M | -4.70% |